Clinical trials: Recurrent or Progressive Glioblastoma
Glioblastoma Multiforme of Brain, Glioma
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic…
- Conditions
- Glioblastoma Multiforme of Brain, Glioma, Glioblastoma
- Trial name
- NCT07464925
- Testing
- GLIX1
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tetragon Biosciences Ltd
Glioblastoma Multiforme
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
This is a Phase 1 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
- Trial name
- NCT05769660
- Testing
- BEY1107, Temozolomide
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- BeyondBio Inc.
Glioblastoma Multiforme
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme.
- Trial name
- NCT00704288
- Testing
- XL184
- Where
- 8 sites in United States
- Volunteers
- 222 people
- Sponsor
- Exelixis
Malignant Glioma, Glioblastoma Multiforme
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma
The purpose of this study is to evaluate the safety and effectiveness of 131I-TM601 in the treatment of adult patients with progressive or recurrent malignant gliomas.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma
- Trial name
- NCT00683761
- Testing
- 131I-TM601
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- TransMolecular
Glioblastoma
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT03679754
- Testing
- Ad-RTS-hIL-12, veledimex
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alaunos Therapeutics
Glioblastoma Multiforme
Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
This study will evaluate if a drug called G-202 can be safely used to treat people with glioblastoma (GBM) that has progressed or recurred. G-202 is given by intravenous infusion on three consecutive days of a 28-day cycle.
- Trial name
- NCT02067156
- Testing
- G-202
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- GenSpera, Inc.
Astrocytoma, Glioblastoma
CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects…
- Trial name
- NCT04047303
- Testing
- CC-90010
- Where
- 4 sites in United States, Spain
- Volunteers
- 20 people
- Sponsor
- Celgene
Glioblastoma Multiforme of Brain
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the…
- Trial name
- NCT05627323
- Testing
- CHM-1101 CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Chimeric Therapeutics
Glioblastoma, Grade IV Astrocytoma
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
This is a single-arm, open-label, multicenter study in approximately 52 adults with primary (de novo) GB that has recurred or progressed (first or second recurrence, including this recurrence) after treatment(s) including surgery…
- Conditions
- Glioblastoma, Grade IV Astrocytoma, Glioblastoma Multiforme, Grade IV Glioma
- Trial name
- NCT02858895
- Testing
- MDNA55
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Medicenna Therapeutics, Inc.
Recurrent Glioblastoma Multiforme (GBM)
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
This was an investigational study to assess the objective overall response (OOR) rate (complete response [CR] + partial response [PR]) of imatinib mesylate and hydroxyurea (hydroxycarbamide) combination therapy in patients with…
- Trial name
- NCT00290771
- Testing
- Imatinib tablets, Hydroxyurea capsules
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- Novartis
Glioblastoma
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human interleukin-12 (IL-12).
- Trial name
- NCT03636477
- Testing
- Ad-RTS-hIL-12, veledimex, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Alaunos Therapeutics
Glioblastoma Multiforme
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with…
- Trial name
- NCT02704858
- Testing
- Perillyl alcohol
- Where
- 11 sites in United States
- Volunteers
- 49 people
- Sponsor
- Neonc Technologies, Inc.
Glioblastoma Multiforme
Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
Investigation on safety, tolerability and efficacy of H-1 parvovirus (H-1PV) in subjects suffering from glioblastoma multiforme.
- Trial name
- ParvOryx01 (NCT01301430)
- Testing
- H-1PV
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Oryx GmbH & Co. KG
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to…
- Trial name
- NCT05765812
- Testing
- Debio 0123, Temozolomide, Radiotherapy
- Where
- 16 sites in United States, Spain and 1 more
- Volunteers
- 116 people
- Sponsor
- Debiopharm International SA
Advanced Solid Tumors, Recurrent or Progressive Glioblastoma
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.
This is a Phase 1, open-label, dose-escalation study of CBX-663 in participants with R/R AML, MDS or CMML (Cohort A), advanced solid tumors (Cohort B), or recurrent or progressive GBM (Cohort C) (collectively called 'indication…
- Conditions
- Advanced Solid Tumors, Recurrent or Progressive Glioblastoma, Relapse or Refractory Myeloid Malignancies
- Trial name
- TelOscope (NCT07779798)
- Testing
- CBX-663
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Crossbow Therapeutics, Inc.
Glioblastoma
A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients
The purpose of the study is to evaluate the feasibility and safety of intra-tumor and interstitial therapy with hBMP4 in increasing doses in patients with progressive and/or multiple recurrent Glioblastoma multiforme (GBM).
- Trial name
- NCT02869243
- Testing
- hrBMP4
- Where
- 4 sites in Israel, Italy and 1 more
- Volunteers
- 15 people
- Sponsor
- Stemgen
Malignant Glioma, Glioblastoma Multiforme
Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma
The purpose of this study is to evaluate the safety and biologically active dose of TM-601 in adult patients with recurrent malignant glioma.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma
- Trial name
- NCT00591058
- Testing
- TM-601
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- TransMolecular
Glioblastoma
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT04006119
- Testing
- Ad-RTS-hIL-12, Veledimex, Cemiplimab-Rwlc
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Alaunos Therapeutics
Glioblastoma
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive…
- Trial name
- NCT06061809
- Testing
- Bevacizumab, PD-L1 t-haNK, N-803
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- ImmunityBio, Inc.
Solid Tumor, Glioblastoma
A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma
This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine the safety and tolerability of a single intratumoral (IT) injection of C5252 in patients with recurrent or progressive glioblastoma…
- Conditions
- Solid Tumor, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain
- Trial name
- NCT05095441
- Testing
- C5252
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- ImmVira Pharma Co. Ltd